Impinj Inc vs Zoetis Inc — how do they compare? Impinj Inc trades at $186.7 (market cap $5.60B), while Zoetis Inc trades at $74.01 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 5.4× Impinj Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Impinj Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Impinj Inc for 22 Days and Zoetis Inc for 70 Days on average.
| PI | ZTS | |
|---|---|---|
Market Cap | $5.60B | $30.20B |
Volume | 9,929 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $241.91 | $147.53 |
52-Week Low | $91.34 | $69.09 |
Typical Hold Time | 22 Days | 70 Days |
Enterprise Value | $5.73B | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
Impinj (PI) trades at $186.53, down 2.36% with a bullish technical outlook despite negative profitability metrics. The stock shows strong analyst support with 16 buy ratings and a $178.83 consensus target. Recent Q2 2026 earnings beat expectations with $0.86 EPS, while revenue growth continues but net margins remain negative at -7.26%. The company maintains solid cash flow from operations of $58.75M in 2025.
Investment outlook balances growth potential against profitability challenges. The RAIN RFID technology market offers expansion opportunities, but elevated valuations (P/S 14.83) and negative ROE (-12.87%) present risks. Near-term catalysts include Q3 2026 results, while competitive pressures and execution risks require monitoring for sustained shareholder value creation.
Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed earnings performance, having beaten estimates in Q2 2026 but missing in Q1. Despite recent headwinds in U.S. companion animal sales, the company maintains strong profitability with 71.67% gross margins and 27.69% net income margins. Analyst consensus remains positive with a $87.33 price target, though technical indicators suggest near-term pressure with support at $70-$71.
Zoetis presents a compelling value opportunity with attractive valuation multiples (P/E 11.92, EV/EBITDA 9.4) and robust fundamentals, though near-term risks include competitive pressures in pet medications and weakening U.S. veterinary clinic traffic. The company's international and livestock segments show resilience, supporting long-term growth potential despite current market skepticism.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →